Denmark-based Genmab A/S has raised $581.8 million from its initial public offering on the US Nasdaq market following a decision by underwriters to fully exercise their over-allotment option and buy more shares. Prior to the option exercise, Genmab had secured gross proceeds of $505.9 million. The final total was announced on 19 July.
